EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    What Changes at Scale, and How Do You Know?

    A pharmaceutical process that performs reliably on a few grams of material can behave very differently at pilot or commercial scale The temperature setpoint that worked on the bench the mixing time that delivered a uniform blend the feed rate that kept a reaction on track none of these is guaranteed to mean the same thing in larger equipment When that difference goes...

KNOWLEDGE BANK

  • Articles

    Single-Use Technologies: Accelerating Flexible Biopharmaceutical Manufacturing

    For most of the past two decades the case for singleuse technologies in biopharmaceutical manufacturing was argued in the language of the plant Disposable bags and flow paths removed cleaninplace and steaminplace loops shortened turnarounds and allowed engineers to stand up a suite without a validation campaign measured in seasons That argument has been won Disposable systems now appear at every s...

    Pharmaceutical Marketing in the Digital Age: Strategies and Challenges

    Currently there is a great advancement in the use of technological solutions particularly under the modern pharma digital era Therefore with increase in knowledge dissemination through internet among the citizenry due to enhanced technology

    Advancements in Spray Drying for Pharmaceutical Formulations

    Spray drying has emerged as a critical technique in the pharmaceutical industry revolutionizing the formulation process Traditional methods for converting liquid solutions into powder form were timeconsuming and lacked control over particle properties

    The 2025 Agenda: Navigating New European Compliance Challenges in Pharma

    EU pharma industry expectate new regulations changes in the year European Medicines Agency EMA and other regulatory authorities in the continent gradually increase regulatory requirements that exercise greater pressure on business entities to implement patientoriented sustainable and innovative production standards

    How Quantum Computing Is Transforming Drug Discovery

    The current medical setting sees technology lead drug development towards faster speeds Quantum computing in drug discovery belongs to an exclusive group of technological advances that drives revolutionary change in science The advanced computational model called quantum computing drives innovation in drug discovery as well as drug testing and pharmaceutical market release Scientists and experts n...

    Accelerated Approval Pathways: Speed Without the Stumbles

    When a therapy for a devastating disease sits finished in a laboratory while patients wait the arithmetic of a traditional approval timeline becomes unbearable Europes accelerated approval pathways were built precisely for this moment to compress the distance between a promising molecule and a prescription pad

TOP ARTICLES

  • 4

    How Quantum Computing Is Transforming Drug Discovery

    Kate Williamson

    The development of pharmaceuticals gets revolutionized through quantum computing because it permits expedited molecule simulations and exact drug development. Research teams using new quantum algorith...

press releases Read more...

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

Erasca Inc Nasdaq ERAS a clinicalstage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RASMAPK pathwaydriven cancers today announced a clinical

Verismo Therapeutics Licenses In Vivo CAR T Engineering Technology to Extend Its Novel Multi-Chain KIR-CAR Platform

Verismo Therapeutics a clinicalstage CAR T cell therapy company pioneering a novel multichain KIRCAR platform technology announced today that the company licensed the PACKIT technology enabling in vivo engineering of KIRCAR

22nd Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech

Pharma organisations are still in a transition process from traditional model centered on blockbuster to more collaborative global ones In order to address the main challenge of RD productivity PPM professional serve as a link between operational teams

Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development

Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX a potential firstinclass small molecule modulator of MYC condensates into clinical development

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

25 - 25

Nov 2026

What’s Next for Pharma Marketing in 2027

Landesmuseum Zürich, Zurich, S...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

LATEST NEWS Read more...

CAI Enters Agreement with PQE Group to Expand Global Life Sciences Services

CAI a professional services firm specialising in operational readiness and excellence for life sciences and other critical industries has entered into a definitive agreement with PQE Group a global consulting firm focused on quality compliance

Erasca Partners with Bristol Myers Squibb to Study ERAS-0015 Combination Therapy for Pancreatic Cancer

Erasca Inc a clinicalstage precision oncology company focused on developing treatments for cancers driven by the RASMAPK signalling pathway has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS

Libtayo Receives EU Approval for Extended Dosing and Shorter Infusion Times Across Six Cancer Indications

Regeneron Pharmaceuticals has received European Commission EC approval for an alternative dosing schedule for Libtayo cemiplimab across all six of its approved indications for skin lung and cervical cancers in the European Union EU

FDA approves Roche’s Wilserdly for ER-positive, ESR1-mutated advanced breast cancer

Roche has received approval from the US Food and Drug Administration FDA for Wilserdly giredestrant in combination with everolimus to treat adults with oestrogen receptor ERpositive human epidermal growth factor receptor HERnegative ESRmutated locally advanced or metastatic breast cancer

European Commission approves Revolution Medicines’ RASONQUE for metastatic pancreatic cancer

Revolution Medicines has received European Commission EC approval for RASONQUE daraxonrasib to treat adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy The medicine is taken once daily as an oral tablet and is approved for patients with or witho...

Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer

Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN